Canaccord Genuity Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Rocket Pharmaceuticals (NASDAQ:RCKT) but lowers the price target from $49 to $40.

July 03, 2024 | 2:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Rocket Pharmaceuticals but lowers the price target from $49 to $40.
The Buy rating suggests continued confidence in Rocket Pharmaceuticals' long-term prospects, but the lowered price target indicates some caution about short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100